THRIVE™ produces T cell therapies utilizing optimized and rapid manufacturing that incorporates gene editing modifications to maximize the therapeutic impact of TCR-T cell therapies. THRIVE™ combines cell therapy manufacturing and gene editing to generate a high yield of fit and proliferative T cells exhibiting naïve and stem cell memory phenotypes. By selecting for stemness and engineering both CD4 T cells and CD8 T cells with our TAILOR™ and TUNE™ platforms, we enhance the potency of TCR-T cells in the presence of tumor-specific antigens and reduce exhaustion in the tumor microenvironment. Novel gene editing systems facilitate advanced cellular engineering including non-viral knock in of TAILOR™ and TUNE™ elements, as well as increased avidity through knock out of the endogenous TCR, which prevents potential mispairing between native and transgenic TCR chains. By modifying cells in a controlled and highly reproducible manner, THRIVE™ aims to improve cellular proliferation, persistence and durability of responses, and ultimately, to eradicate metastatic cells in patients with solid tumors.
